Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company Deals

Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development

Fineline Cube Dec 7, 2022

Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD...

Company Deals

Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing

Fineline Cube Dec 7, 2022

Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of...

Company Deals

Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments

Fineline Cube Dec 7, 2022

China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to...

Policy / Regulatory

NHSA Delays NRDL Negotiations Due to COVID-19 Disruptions

Fineline Cube Dec 7, 2022

The National Healthcare Security Administration (NHSA) announced that it has been decided to delay the...

Company Deals

MaxHealth Biotechnology Completes Series B+ Financing Round

Fineline Cube Dec 7, 2022

Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...

Company Drug

MicuRx Pharmaceuticals Gains Clinical Trial Approvals for MRX-4 in Europe

Fineline Cube Dec 7, 2022

Sino-US firm MicuRx Pharmaceuticals Inc. announced receiving clinical trial approvals in France, Greece, Hungary, Italy,...

Company Deals

F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again

Fineline Cube Dec 7, 2022

UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...

Company Deals

ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy

Fineline Cube Dec 6, 2022

Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...

Company Drug

Beijing Wantai’s Nasal Spray COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 6, 2022

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced the inclusion of its...

Company Deals

Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform

Fineline Cube Dec 6, 2022

Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...

Hospital

Hainan’s First Integrated Bladder Cancer Center Launched at Provincial Urology Meeting

Fineline Cube Dec 6, 2022

The first Integrated Bladder Cancer Center (IBCC) in Hainan province was inaugurated in Hainan General...

Deals Hospital

United Family Healthcare Partners with HSS for Orthopedic Collaboration

Fineline Cube Dec 6, 2022

United Family Healthcare (UFH), a private comprehensive medical institution based in Beijing, announced an agreement...

Company Medical Device

MicroPort MedBot’s Orthopedic Surgery Robot Receives CE Certification

Fineline Cube Dec 6, 2022

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced receiving a CE certification in Europe...

Company Drug

Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers

Fineline Cube Dec 6, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...

Company Deals

Akeso Biopharma Plans IPO on Shanghai’s STAR Market

Fineline Cube Dec 6, 2022

China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...

Company

Novo Nordisk and ATLATL Announce Winners of EntreStar Program for Pharma Start-Ups

Fineline Cube Dec 6, 2022

Novo Nordisk Research Centre China (NNRCC) and the innovation incubator ATLATL jointly announced the winners...

Company Deals

Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets

Fineline Cube Dec 6, 2022

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...

Company Drug

WestVac Biopharma’s Recombinant COVID-19 Vaccine Approved for Emergency Use in China

Fineline Cube Dec 5, 2022

Chengdu-based WestVac Biopharma Co., Ltd announced the inclusion of its recombinant COVID-19 vaccine (Sf9 cells)...

Company Drug

Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study

Fineline Cube Dec 5, 2022

China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...

Company Deals Digital

China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma

Fineline Cube Dec 5, 2022

China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...

Posts pagination

1 … 541 542 543 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.